Drug Profile
Research programme: viral infection therapies - PTC Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PTC Therapeutics
- Class Small molecules
- Mechanism of Action Viral protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dengue; HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Dengue in USA (PO)
- 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in USA
- 22 Oct 2012 PTC Therapeutics receives grant from the National Institutes of Health to support research for the treatment of Dengue fever